Abstract
Madeng’ai, the dried root of Potentilla freyniana Bornm., is used in Dong medicine for infections and wound care. This study examined the chemical composition and prophylactic protective effects of the ethyl acetate fraction of its ethanolic root extract (referred to as MEA) in lipopolysaccharide (LPS)-induced acute lung injury (ALI). Ultra-high-performance liquid chromatography coupled to Q-Exactive Orbitrap mass spectrometry detected 77 constituents, comprising 13 compounds authenticated with reference standards and 64 constituents tentatively annotated from accurate mass and tandem mass spectrometry (MS/MS) fragmentation. Network pharmacology prioritized six candidate compounds, 120 overlapping targets, and nine hub targets, and molecular docking explored theoretical interactions with inflammation-related proteins. MEA was evaluated in LPS-stimulated MH-S alveolar macrophages and in male C57BL/6J mice receiving oral pretreatment for seven days prior to intraperitoneal LPS challenge. In MH-S cells, MEA pretreatment reduced nitrite, interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA)-detectable intracellular oxidative fluorescence, and Nlrp3, Pycard, Casp1, and Gsdmd mRNA levels. In mice, seven-day oral pretreatment with MEA attenuated qualitative histological lung injury, pulmonary edema, and serum cytokine elevation, accompanied by lower lung protein levels of NOD-like receptor family pyrin domain-containing 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), pro-caspase-1, and the ~30 kDa N-terminal fragment of gasdermin D (GSDMD-N), together with related transcripts. These findings indicate that prophylactic MEA administration attenuates LPS-induced macrophage inflammation and experimental lung injury, accompanied by reduced intracellular oxidative stress and decreased expression of NLRP3–GSDMD pathway-associated markers.
Keywords: Potentilla freyniana, acute lung injury, NLRP3 inflammasome, gasdermin D, oxidative stress, network pharmacology
1. Introduction
Acute lung injury (ALI) is characterized by inflammatory damage to the alveolar epithelium and pulmonary capillary endothelium. Disruption of this barrier promotes alveolar and interstitial edema, impairs gas exchange, and contributes to acute respiratory distress syndrome (ARDS) [1,2]. Supportive care remains central to management, while pharmacological control of the underlying inflammatory injury remains challenging. The interaction between inflammatory responses and barrier dysfunction makes pulmonary inflammation an important focus of experimental ALI research.
The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome connects innate immune sensing with inflammatory cell injury. It comprises the NLRP3 sensor, the adaptor apoptosis-associated speck-like protein containing a CARD (ASC), and pro-caspase-1 [3,4]. Inflammasome assembly facilitates caspase-1 activation, cytokine maturation, and gasdermin D (GSDMD) cleavage. The resulting N-terminal fragment, GSDMD-N, forms membrane pores that support cytokine release and pyroptotic cell death [5,6]. In experimental ALI, excessive NLRP3 signaling contributes to macrophage inflammatory responses and pulmonary barrier injury [7,8]. This pathway therefore offers a biological focus for investigating agents that attenuate lung inflammation.
Plants of the genus Potentilla (Rosaceae) are rich sources of polyphenols, flavonoids, and triterpenoids with documented anti-inflammatory, antioxidant, and antimicrobial activities [9]. Potentilla freyniana Bornm., whose dried root is known as Madeng’ai in traditional Dong medicine in China, has long been used ethnomedicinally for bacterial infections, traumatic bleeding, and inflammatory wound care [10]. Phytochemical investigations of P. freyniana have identified diverse secondary metabolites, including flavan-3-ols, oligomeric procyanidins, flavonols, dihydrochalcones, hydrolysable tannins, and ursane- or oleanane-type pentacyclic triterpenoids such as rosamultin, pomolic acid, and ursolic acid [11,12]. Preclinical studies have reported that extracts and constituents of P. freyniana exhibit antimicrobial activity [10], selective cytotoxicity [12,13], and anti-inflammatory efficacy in experimental gouty arthritis via modulation of mitogen-activated protein kinase (MAPK)/nuclear factor-κB (NF-κB)/NLRP3 signaling [14], although clinical studies have not yet been conducted. While our recent integrated multi-omics study showed that the ethyl acetate fraction of Madeng’ai mitigated lipopolysaccharide (LPS)-induced ALI in mice at the level of global metabolic and transcriptomic remodeling [15], its reference-standard-authenticated chemical profile, its direct anti-inflammatory and redox effects in alveolar macrophages, and its impact on pulmonary NLRP3–GSDMD pathway-related marker expression remained uncharacterized. In the present study, using an independent experimental dataset, we authenticated 13 constituents among 77 ultra-high-performance liquid chromatography coupled to Q-Exactive Orbitrap mass spectrometry (UHPLC-Q-Exactive Orbitrap MS) peaks using reference standards, prioritized candidate targets via network pharmacology and molecular docking, and evaluated whether prophylactic administration of the ethyl acetate fraction of the ethanolic root extract of Madeng’ai (MEA) attenuates LPS-induced oxidative and inflammatory responses in MH-S alveolar macrophages and downregulates NLRP3–GSDMD pathway-associated markers in murine ALI.
2. Results
2.1. Chemical Composition of MEA
UHPLC-Q-Exactive Orbitrap MS detected 77 constituents in MEA, including 34 flavonoids, 28 tannins, 10 triterpenoids, four organic acids, and one phytosterol (Supplementary Table S1). Among these, 13 compounds were unambiguously confirmed by matching retention times, accurate mass, and tandem mass spectrometry (MS/MS) spectra with authentic reference standards: gallic acid, procyanidin B1, catechin, taxifolin, epicatechin gallate, ellagic acid, phlorizin, quercetin, naringenin, phloretin, rosamultin, pomolic acid, and ursolic acid (Table 1). The remaining 64 constituents were tentatively annotated on the basis of accurate mass and MS/MS fragmentation patterns without reference-standard verification. This qualitative LC-MS analysis was designed for structural profiling and reference-standard authentication; absolute concentrations and relative peak area percentages of individual constituents in MEA were not quantified. Base peak chromatograms in positive and negative ion modes are shown in Figure 1.
Table 1.
Constituents of MEA confirmed with reference standards by UHPLC-Q-Exactive Orbitrap MS.
| No. | tR (min) | Adduct | Theoretical m/z | Measured m/z | Error (ppm) | Formula | MS/MS Fragments (m/z, Relative Abundance %) | Identification |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.68 | [M − H]− | 169.01424 | 169.01312 | −6.67 | C7H6O5 | 125.0230 (100) | Gallic acid |
| 2 | 6.82 | [M + H]+/[M − H]− | 579.14970/577.13515 | 579.14911/577.13464 | −1.02/ −0.88 |
C30H26O12 | 289.0716 (100), 125.0232 (83), 407.0766 (69) | Procyanidin B1 |
| 3 | 7.45 | [M + H]+/[M − H]− | 291.08631/289.07176 | 291.08582/289.07144 | −1.70/ −1.11 |
C15H14O6 | 109.0281 (100), 123.0438 (78), 125.0230 (50) | Catechin |
| 4 | 12.76 | [M − H]− | 303.05102 | 303.05075 | −0.91 | C15H12O7 | 125.0231 (100), 175.0390 (17), 151.0026 (12) | Taxifolin |
| 5 | 13.01 | [M + H]+/[M − H]− | 443.09727/441.08271 | 443.09689/441.08231 | −0.87/ −0.93 |
C22H18O10 | 169.0131 (100), 289.0715 (36), 125.0231 (29) | Epicatechin gallate |
| 6 | 13.09 | [M − H]− | 300.99899 | 300.99869 | −1.00 | C14H6O8 | 229.0135 (100), 201.0185 (63), 185.0238 (60) | Ellagic acid |
| 7 | 14.04 | [M − H]− | 435.12967 | 435.12912 | −1.26 | C21H24O10 | 167.0339 (100), 273.0766 (76), 125.0231 (11) | Phlorizin |
| 8 | 16.30 | [M − H]− | 301.03537 | 301.03519 | −0.62 | C15H10O7 | 151.0026 (100), 107.0125 (45), 178.9975 (15) | Quercetin |
| 9 | 17.71 | [M + H]+/[M − H]− | 273.07575/271.06119 | 273.07544/271.06104 | −1.14/ −0.58 |
C15H12O5 | 119.0489 (100), 107.0125 (45), 151.0026 (39) | Naringenin |
| 10 | 17.82 | [M − H]− | 273.07684 | 273.07666 | −0.68 | C15H14O5 | 123.0439 (100), 119.0489 (75), 167.0339 (55) | Phloretin |
| 11 | 19.09 | [M − H]− | 649.39572 | 649.39435 | −2.11 | C36H58O10 | 487.3425 (100) | Rosamultin |
| 12 | 24.66 | [M + H]+/[M − H]− | 473.36253/471.34798 | 473.36209/471.34726 | −0.94/ −1.53 |
C30H48O4 | — | Pomolic acid |
| 13 | 26.40 | [M + H]+/[M − H]− | 457.36762/455.35306 | 457.36670/455.35266 | −2.02/ −0.90 |
C30H48O3 | — | Ursolic acid |
Notes: All 13 compounds were confirmed by comparison of retention time and MS/MS spectra with reference standards analyzed under identical conditions. —, no informative fragment ions. Abbreviations: MEA, ethyl acetate extract of Madeng’ai; MS/MS, tandem mass spectrometry; tR, retention time; UHPLC, ultra-high-performance liquid chromatography.
Figure 1.

Base peak chromatograms of MEA acquired by UHPLC-Q-Exactive Orbitrap MS in (A) positive and (B) negative ionization modes. Peaks correspond to constituents listed in Table 1 and Supplementary Table S1.
2.2. Candidate Compounds and MEA-ALI Targets
Six detected constituents met the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) screening thresholds of oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18, comprising two reference-standard-confirmed compounds (ellagic acid and quercetin) and four compounds tentatively annotated by MS/MS (β-sitosterol, betulinic acid, kaempferol, and isorhamnetin) (Figure 2B; Table 2). Target prediction yielded 506 compound-related targets, while GeneCards, Online Mendelian Inheritance in Man (OMIM), and Therapeutic Target Database (TTD) yielded 742 ALI-related targets (Figure 2C–E). The intersection contained 120 candidate MEA-ALI targets (Figure 2F), which were used for exploratory network and enrichment analyses.
Figure 2.

Extract preparation, candidate compounds, and target acquisition. (A) Preparation of MEA from the dried roots of Potentilla freyniana Bornm. (B) Structures of the six candidate compounds meeting the TCMSP thresholds (OB ≥ 30% and DL ≥ 0.18). (C) Databases used for compound–target prediction (SwissTargetPrediction, Super-PRED, and PharmMapper) and ALI-related target collection (GeneCards, OMIM, and TTD). (D) Targets predicted for the candidate compounds. (E) ALI-related targets from the three disease databases. (F) Intersection yielding 120 candidate MEA-ALI targets. Distinct colors in (C–F) differentiate individual databases and target sets.
Table 2.
Candidate MEA compounds meeting the TCMSP screening thresholds.
| Compound | Class | Formula | MW | No. in Table S1 | Identification | Role in This Study |
|---|---|---|---|---|---|---|
| β-Sitosterol | Phytosterol | C29H50O | 414.71 | 77 | Tentative (MS/MS) | Candidate compound in network analysis |
| Betulinic acid | Triterpenoid | C30H48O3 | 456.71 | 76 | Tentative (MS/MS) | Candidate compound in network analysis |
| Kaempferol | Flavonoid | C15H10O6 | 286.24 | 74 | Tentative (MS/MS) | Representative ligand for NFKB1 docking |
| Isorhamnetin | Flavonoid | C16H12O7 | 316.26 | 75 | Tentative (MS/MS) | Representative ligand for EGFR docking |
| Ellagic acid | Tannin-related polyphenol | C14H6O8 | 302.19 | 51 | Reference standard | Representative ligand for caspase-1 docking |
| Quercetin | Flavonoid | C15H10O7 | 302.24 | 61 | Reference standard | Representative ligand for NLRP3 docking |
Notes: Candidate compounds met oral bioavailability ≥ 30% and drug-likeness ≥ 0.18 in TCMSP. MW, molecular weight (g/mol) calculated from the molecular formula. Abbreviations: EGFR, epidermal growth factor receptor; MEA, ethyl acetate extract of Madeng’ai; MS/MS, tandem mass spectrometry; NFKB1, nuclear factor kappa B subunit 1; NLRP3, NOD-like receptor family pyrin domain-containing 3; TCMSP, Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform.
2.3. PPI Network and Enrichment of the 120 Candidate Targets
The 120 candidate MEA-ALI targets formed a densely connected STRING network at an interaction score greater than 0.7 (Figure 3A,B). Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment highlighted PI3K-Akt, HIF-1, Toll-like receptor, IL-17, MAPK, TNF, and NOD-like receptor signaling, together with pathways related to regulated cell death (Figure 3C); the inclusion of NLRP3 and CASP1 among the candidate targets guided our subsequent experimental evaluation of NLRP3–GSDMD pathway markers. Enriched Gene Ontology (GO) terms included lipopolysaccharide-mediated signaling, inflammatory and interleukin responses, canonical NF-κB signaling, kinase activity, and transcription-factor binding (Figure 3D).
Figure 3.

PPI network and functional enrichment of the 120 candidate MEA-ALI targets. (A) STRING network (interaction score > 0.7). (B) Cytoscape visualization; node size and color reflect degree. (C) KEGG pathway enrichment; dot size indicates gene count and color indicates significance. (D) GO enrichment of biological process (BP), cellular component (CC), and molecular function (MF) terms.
2.4. Hub Targets Involved in Inflammatory Signaling
Ranking by maximal clique centrality, degree, closeness, and betweenness identified nine overlapping hub targets: AKT1, EGFR, ESR1, IL1B, IL6, NFKB1, SRC, STAT3, and TNF. Their relationships with MEA and the six candidate compounds are shown in the compound–target–disease network (Figure 4A), and the topological screening is shown in Figure 4B. GO and KEGG analyses linked these predicted hub targets to LPS-responsive inflammatory signaling, cytokine production, and the NF-κB, Toll-like receptor, TNF, JAK-STAT, IL-17, MAPK, HIF-1, and NOD-like receptor pathways (Figure 4C,D). Functional descriptions of the nine targets are provided in Table 3.
Figure 4.

Hub-target screening and pathway interpretation. (A) Compound–target–disease network linking MEA, the six candidate compounds, ALI, and the nine hub targets. (B) Hub-target screening by maximal clique centrality, degree, closeness, and betweenness in cytoHubba; the intersection identified AKT1, EGFR, ESR1, IL1B, IL6, NFKB1, SRC, STAT3, and TNF. (C) GO enrichment of the nine hub targets. (D) Chord diagram linking hub targets to inflammation-related KEGG pathways.
Table 3.
Hub targets and their principal biological functions.
| Gene Symbol | Full Name | Main Biological Role |
|---|---|---|
| AKT1 | AKT serine/threonine kinase 1 | PI3K-Akt survival and inflammatory signaling |
| EGFR | Epidermal growth factor receptor | Epithelial injury response; MAPK/PI3K-Akt activation |
| ESR1 | Estrogen receptor 1 | Immune modulation and transcriptional regulation |
| IL1B | Interleukin 1 beta | Inflammasome-related pro-inflammatory cytokine |
| IL6 | Interleukin 6 | Acute inflammatory cytokine; JAK-STAT signaling |
| NFKB1 | Nuclear factor kappa B subunit 1 | Inflammatory transcription and inflammasome priming |
| SRC | SRC proto-oncogene, non-receptor tyrosine kinase | Receptor-linked kinase and inflammatory signaling |
| STAT3 | Signal transducer and activator of transcription 3 | Cytokine signaling and inflammatory repair |
| TNF | Tumor necrosis factor | Central cytokine in inflammatory amplification |
Abbreviations: AKT1, AKT serine/threonine kinase 1; EGFR, epidermal growth factor receptor; ESR1, estrogen receptor 1; IL1B, interleukin 1 beta; IL6, interleukin 6; NFKB1, nuclear factor kappa B subunit 1; SRC, SRC proto-oncogene; STAT3, signal transducer and activator of transcription 3; TNF, tumor necrosis factor.
2.5. Docking of Candidate Compounds with Inflammation-Related Targets
Predicted AutoDock Vina binding energies for the six candidate compounds across the screened targets are shown in Figure 5A. Four representative complexes were examined in detail to illustrate potential binding modes for the network-derived hubs NFKB1 and EGFR and the inflammasome-related proteins caspase-1 and NLRP3. Their predicted binding energies ranged from −6.8 to −8.2 kcal/mol: −6.8 kcal/mol for kaempferol-NFKB1, −8.2 kcal/mol for isorhamnetin-EGFR, −7.1 kcal/mol for ellagic acid-caspase-1, and −8.2 kcal/mol for quercetin-NLRP3. Predicted NFKB1 pocket contacts included Ser63, His64, Gly66, and Pro68. EGFR contacts included Leu132, Val140, Ala156, Lys158, Ile190, Thr205, Ala208, Leu259, and Asp270. Caspase-1 contacts included Ser129, Arg161, Gln194, Gly197, and Ser199, while NLRP3 contacts included Thr169, Pro412, Leu413, and Trp416 (Figure 5B–E).
Figure 5.

Molecular docking of candidate MEA compounds. (A) Dot map of AutoDock Vina binding energies (kcal/mol) for the six candidate compounds and the selected targets. (B–E) Two-dimensional interaction diagrams, three-dimensional overviews, and binding-pocket views for kaempferol-NFKB1 (PDB 1VKX) (B), isorhamnetin-EGFR (PDB 1M17) (C), ellagic acid-caspase-1 (PDB 1RWK) (D), and quercetin-NLRP3 (PDB 7PZC) (E). Dashed lines indicate hydrogen bonds and other non-covalent contacts. In (A), dot color and size reflect the predicted binding energy (kcal/mol); in (B–E), distinct colors distinguish the protein receptor, ligand, and interacting amino acid residues.
2.6. Selection of Non-Cytotoxic MEA Concentrations
After 24 h of incubation, MH-S cell viability relative to the untreated control (100.21 ± 1.22%; normalized to 100.00%) was 101.78 ± 4.09% at 20 μg/mL, 101.97 ± 4.09% at 40 μg/mL, and 100.01 ± 2.55% at 80 μg/mL (p > 0.05 for all three concentrations versus 0 μg/mL), whereas viability decreased significantly to 71.87 ± 3.09% at 160 μg/mL and 58.63 ± 2.17% at 320 μg/mL (p < 0.001 versus 0 μg/mL; Figure 6). Because mean viability remained at ~100% across 20 to 80 μg/mL, any effect on basal cell survival within this concentration range was both statistically non-significant and biologically negligible, and 20, 40, and 80 μg/mL were therefore selected for subsequent cell experiments.
Figure 6.

Effect of MEA on MH-S cell viability. Cells were treated with MEA (0–320 μg/mL) for 24 h, and viability was measured by Cell Counting Kit-8 (CCK-8) assay. Data are mean ± SD of n = 3 independent biological experiments; one-way ANOVA with Tukey’s test. *** p < 0.001 versus 0 μg/mL.
2.7. MEA Reduces Inflammatory Mediator Release in LPS-Stimulated MH-S Cells
LPS stimulation significantly increased nitrite accumulation and interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α concentrations in MH-S cell supernatants compared with the Control group (p < 0.001). Two-hour pretreatment with MEA at 20, 40, and 80 μg/mL significantly reduced all four inflammatory mediators relative to the LPS group (p < 0.001), with numerically lower group means observed at 40 and 80 μg/mL than at 20 μg/mL (Figure 7A–D). Pretreatment with dexamethasone (DEX; 1 μg/mL) similarly decreased the levels of these mediators (p < 0.001).
Figure 7.

MEA reduces inflammatory mediator release in LPS-stimulated MH-S cells. Cells were pretreated with MEA (20, 40, or 80 μg/mL) or DEX (1 μg/mL) for 2 h and stimulated with LPS (1 μg/mL) for 24 h. (A) Nitrite (% of LPS), (B) IL-1β, (C) IL-6, and (D) TNF-α in culture supernatants. Data are mean ± SD of n = 3 independent biological experiments; one-way ANOVA with Tukey’s test. ### p < 0.001 versus Control; *** p < 0.001 versus LPS. “+” and “−” indicate the presence and absence of the corresponding treatment, respectively.
2.8. MEA Reduces ROS-Related Oxidative Fluorescence in LPS-Stimulated MH-S Cells
LPS stimulation markedly increased intracellular 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescence compared with Control cells (p < 0.001). Pretreatment with DEX and all three MEA concentrations significantly reduced this reactive oxygen species (ROS)-related oxidative fluorescence signal relative to the LPS group (p < 0.01 at 20 μg/mL; p < 0.001 at 40 and 80 μg/mL), with progressively lower group mean fluorescence intensity observed across 20, 40, and 80 μg/mL MEA (Figure 8A,B).
Figure 8.

MEA reduces intracellular ROS-related oxidative fluorescence in LPS-stimulated MH-S cells. (A) Representative DCFH-DA fluorescence images. Scale bars: 100 μm. (B) Relative fluorescence intensity (a.u.), calculated as the mean green-channel intensity of each whole field. Data are mean ± SD of n = 3 independent biological experiments; dots show individual experiments. One-way ANOVA with Tukey’s test. ### p < 0.001 versus Control; ** p < 0.01, *** p < 0.001 versus LPS. “+” and “−” indicate the presence and absence of the corresponding treatment, respectively.
2.9. MEA Downregulates NLRP3–GSDMD Pathway Genes in MH-S Cells
LPS stimulation significantly increased Nlrp3, Pycard, Casp1, and Gsdmd mRNA expression in MH-S cells compared with the Control group (p < 0.001). Pretreatment with DEX and MEA (20, 40, and 80 μg/mL) significantly reduced these transcript levels relative to the LPS group (p < 0.01 or p < 0.001), with progressively lower mean transcript levels observed from 20 to 80 μg/mL MEA (Figure 9A–D).
Figure 9.

MEA decreases NLRP3–GSDMD pathway-related gene expression in LPS-stimulated MH-S cells. Nlrp3 (A), Pycard (B), Casp1 (C), and Gsdmd (D) mRNA levels were measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR), normalized to Actb, and expressed relative to Control. Data are mean ± SD of n = 3 independent biological experiments; one-way ANOVA with Tukey’s test. ### p < 0.001 versus Control; ** p < 0.01, *** p < 0.001 versus LPS. “+” and “−” indicate the presence and absence of the corresponding treatment, respectively.
2.10. MEA Attenuates Lung Injury, Edema, and Circulating Cytokines in ALI Mice
Qualitative histological examination of hematoxylin and eosin (H&E)-stained lung sections showed pronounced alveolar septal thickening, inflammatory-cell accumulation, and disruption of normal alveolar architecture in the LPS group, whereas these morphological alterations appeared less extensive in mice receiving seven-day oral pretreatment with DEX or MEA (Figure 10A). Quantitatively, LPS challenge significantly increased the lung wet/dry weight ratio compared with the Control group (p < 0.001), whereas oral pretreatment with DEX or MEA (100, 200, and 400 mg/kg) significantly reduced this index of pulmonary edema (p < 0.05 or p < 0.01 versus LPS; Figure 10B). Serum IL-1β, IL-6, and TNF-α concentrations were also markedly elevated 12 h after LPS challenge (p < 0.001) and were significantly lower in mice pretreated with DEX or MEA across the 100 to 400 mg/kg dose range (p < 0.001 versus LPS; Figure 10C–E).
Figure 10.

MEA attenuates lung injury, edema, and serum cytokines in LPS-induced ALI mice. Mice received MEA (100, 200, or 400 mg/kg) or DEX (5 mg/kg) by oral gavage once daily for 7 days, followed by LPS (20 mg/kg, i.p.) for 12 h. (A) Representative H&E-stained lung sections. Scale bars: 50 μm. (B) Lung wet/dry weight ratio. (C–E) Serum IL-1β (C), IL-6 (D), and TNF-α (E). Data are mean ± SD, n = 10 mice per group; one-way ANOVA with Tukey’s test. ### p < 0.001 versus Control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus LPS. “+” and “−” indicate the presence and absence of the corresponding treatment, respectively.
2.11. MEA Decreases Lung NLRP3–GSDMD Pathway Proteins and Transcripts
LPS challenge significantly increased lung protein levels of NLRP3, ASC, pro-caspase-1 (~45 kDa), and the ~30 kDa GSDMD-N cleavage fragment compared with the Control group (p < 0.01 or p < 0.001), whereas seven-day oral pretreatment with DEX or MEA (100, 200, and 400 mg/kg) significantly reduced the levels of these four protein markers relative to the LPS group (Figure 11A–E). Concordantly, lung Nlrp3, Pycard, Casp1, and Gsdmd mRNA levels were significantly elevated after LPS challenge (p < 0.001, n = 10 mice per group) and were significantly decreased following pretreatment with DEX or MEA (Figure 11F–I).
Figure 11.

MEA decreases lung NLRP3–GSDMD pathway-related protein and gene expression in LPS-induced ALI mice. (A) Representative Western blots of NLRP3, ASC, pro-caspase-1 (~45 kDa), GSDMD-N (~30 kDa), and β-actin in lung tissue. (B–E) Densitometry normalized to β-actin (n = 3 randomly selected mice per group). (F–I) Nlrp3, Pycard, Casp1, and Gsdmd mRNA normalized to Actb (n = 10 mice per group). Data are mean ± SD; one-way ANOVA with Tukey’s test. ## p < 0.01, ### p < 0.001 versus Control; * p < 0.05, ** p < 0.01, *** p < 0.001 versus LPS. “+” and “−” indicate the presence and absence of the corresponding treatment, respectively.
3. Discussion
Seven-day oral pretreatment with MEA attenuated LPS-induced pulmonary edema, histological lung injury, and systemic cytokine elevation in mice while suppressing inflammatory mediator release in LPS-stimulated MH-S alveolar macrophages. These protective effects were accompanied by lower intracellular DCFH-DA oxidative fluorescence and reduced expression of NLRP3–GSDMD pathway-associated transcripts and proteins (Figure 12). These findings both corroborate and extend our recently published multi-omics study of the ethyl acetate fraction of Madeng’ai in murine ALI [15]. While the earlier study used an independent animal cohort to profile global pulmonary transcriptomic and metabolomic remodeling and relied on tentative untargeted MS annotation [15], the present independent dataset advances those observations by authenticating 13 marker constituents of MEA with reference standards alongside 64 MS/MS-annotated peaks (Table 1; Supplementary Table S1), demonstrating direct anti-inflammatory and redox-modulating effects in cultured MH-S alveolar macrophages, and showing that MEA downregulates Nlrp3, Pycard, Casp1, and Gsdmd mRNA as well as NLRP3, ASC, pro-caspase-1, and ~30 kDa GSDMD-N protein levels in lung tissue.
Figure 12.

Summary of chemical profiling and proposed associative mechanism of MEA in LPS-induced acute lung injury. The schematic links MEA constituents and computationally predicted targets with reduced macrophage inflammatory mediator release and ROS-related oxidative fluorescence, decreased lung expression of NLRP3, ASC, pro-caspase-1, and the ~30 kDa GSDMD-N fragment, and alleviated lung injury following prophylactic administration. Blunt-ended lines indicate associative downregulation of pathway markers.
Given the chemical complexity of MEA, network pharmacology was used to prioritize candidate inflammatory pathways. The 120 overlapping targets were enriched in LPS-responsive signaling, and the nine topological hub targets included IL1B, IL6, TNF, and NFKB1—aligning with the pro-inflammatory cytokines reduced in our macrophage and mouse experiments and with NF-κB-dependent transcriptional priming of the inflammasome. Because database target predictions and fixed TCMSP thresholds (OB ≥ 30% and DL ≥ 0.18) favor small orally absorbable molecules and four of the six filtered candidates (kaempferol, isorhamnetin, betulinic acid, and β-sitosterol) were tentatively annotated by MS/MS, the network and KEGG enrichment results (including untested pathways such as PI3K-Akt, HIF-1, MAPK, and IL-17) serve as hypothesis-generating prioritizations.
Reference-standard authentication confirmed that MEA contains both polyphenols/flavonoids (gallic acid, procyanidin B1, catechin, taxifolin, epicatechin gallate, ellagic acid, phlorizin, quercetin, naringenin, and phloretin) and ursane-type pentacyclic triterpenoids (rosamultin, pomolic acid, and ursolic acid). Prior studies have shown that quercetin, ellagic acid, and catechins suppress macrophage oxidative stress and cytokine production [16,17,18], while ursolic acid and pomolic acid inhibit NF-κB activation, attenuate reactive oxygen species generation, and reduce IL-1β release in experimental inflammation [12,13,19,20]. Because our UHPLC-Q-Exactive Orbitrap MS analysis was qualitative and biological assays were conducted with the whole MEA fraction, purified-monomer and combination assays will be needed to determine the individual potency and potential interactions of these constituents. In MH-S macrophages, MEA reduced DCFH-DA oxidative fluorescence [21] alongside inflammasome-related transcripts, consistent with coordinated attenuation of macrophage oxidative stress and inflammatory signaling [22,23].
Molecular docking examined theoretical binding complementarity between selected candidate constituents and the network hubs NFKB1 and EGFR as well as the inflammasome-related proteins NLRP3 and caspase-1. The predicted binding energies (−6.8 to −8.2 kcal/mol) and hydrogen-bonding contacts within static crystal structures provide structural hypotheses for how polyphenols and flavonoids in MEA may interact with inflammatory signaling proteins [24], offering candidate compound–target pairs for future biophysical binding and target-engagement studies.
In canonical inflammasome signaling, caspase-1 activation cleaves GSDMD to release the N-terminal fragment GSDMD-N, which forms plasma membrane pores and drives inflammatory cell injury [5,6]. Here, prophylactic MEA administration reduced lung NLRP3, ASC, pro-caspase-1 (~45 kDa), and ~30 kDa GSDMD-N protein levels (assessed by Western blot in n = 3 randomly selected mice per group) alongside Nlrp3, Pycard, Casp1, and Gsdmd mRNA in macrophages and lung tissue (n = 10 mice per group), accompanying improvements in pulmonary edema and systemic cytokines [7,8]. These coordinated reductions indicate that MEA dampens NLRP3–GSDMD pathway expression and upstream inflammatory priming in LPS-challenged lungs; direct functional assays—including cleaved caspase-1 (p20) activity, ASC oligomerization, lactate dehydrogenase release, propidium iodide uptake, and selective NLRP3 inhibition or knockdown—will be required to determine whether MEA directly blocks inflammasome assembly and pyroptotic pore formation.
Several additional study boundaries merit consideration. First, although a single chemically fingerprinted batch of MEA (extraction yield 4.80%, w/w) was used across all experiments, multi-batch quantitative standardization of marker constituents and in vivo pharmacokinetic profiling [25] remain to be established. Second, acute lung injury was induced in male C57BL/6J mice by systemic intraperitoneal LPS injection (20 mg/kg for 12 h) following 7-day oral MEA pretreatment, which models prophylactic protection against endotoxemia-associated indirect lung injury; future studies should evaluate both sexes and post-challenge therapeutic administration in direct intrapulmonary ARDS models [26]. Third, pulmonary H&E histology was evaluated qualitatively alongside quantitative lung wet/dry weight ratios and serum cytokine measurements, and incorporating blinded histological scoring will further strengthen pathological assessment.
4. Materials and Methods
4.1. Plant Material, Extract Preparation, and Reagents
Madeng’ai roots (Potentilla freyniana Bornm.) were provided by the Hunan Provincial Key Laboratory of Dong Medicine and authenticated by Prof. Zaiqi Zhang (Hunan University of Medicine). A voucher specimen (No. Cl-1-10-1) was deposited at the Hunan Provincial Key Laboratory of Dong Medicine (Huaihua, China). Dried roots (5.0 kg) were pulverized and macerated in 95% ethanol at a solid-to-liquid ratio of 1:10 (w/v) at room temperature for 7 days, and extraction was repeated three times. The combined ethanolic filtrates were concentrated under reduced pressure to remove ethanol, suspended in distilled water at a ratio of 1:1.5 (w/v), and successively partitioned three times with an equal volume of ethyl acetate (1:1, v/v). The combined ethyl acetate layers were concentrated under reduced pressure and dried to yield 240 g of the ethyl acetate fraction of the ethanolic root extract of Madeng’ai (referred to as MEA; extraction yield 4.80%, w/w, relative to dried crude root). A single homogenized batch of MEA, chemically fingerprinted by UHPLC-Q-Exactive Orbitrap MS, was stored in sealed amber vials at 4 °C in the dark until use across all experiments. Dexamethasone (DEX; ST1254) was purchased from Beyotime Biotechnology (Shanghai, China), and LPS (L2880) was obtained from Sigma-Aldrich (St. Louis, MO, USA).
HPLC-grade acetonitrile and methanol were purchased from Merck KGaA (Rahway, NJ, USA). Purified water was obtained from Watsons (Changsha, China), and formic acid was provided by Fisher Scientific (Fair Lawn, NJ, USA). Reference standards were sourced as follows: gallic acid and epicatechin gallate from Chengdu Zhibiao Chemical Pure Biotechnology Co., Ltd. (Chengdu, China); catechin and quercetin from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai, China); taxifolin and ellagic acid from Chengdu Alfa Biotechnology Co., Ltd. (Chengdu, China); procyanidin B1 from Sichuan Vicki Biotechnology Co., Ltd. (Chengdu, China); phlorizin from Chengdu Lemeitian Pharmaceutical Technology Co., Ltd. (Chengdu, China); naringenin from Chengdu Herbpurify Co., Ltd. (Chengdu, China); phloretin from Nanjing Spring & Autumn Biological Engineering Co., Ltd. (Nanjing, China); and ursolic acid from the National Institutes for Food and Drug Control (Beijing, China). Rosamultin and pomolic acid were isolated in our laboratory. The purity of all reference standards was greater than 98%. All other solvents were of analytical grade.
4.2. UHPLC-Q-Exactive Orbitrap MS Analysis
UHPLC analysis was performed using an Ultimate 3000 system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with a Thermo Scientific Syncronis aQ column (100 mm × 2.1 mm, 1.7 μm) maintained at 40 °C. The mobile phases were 0.1% formic acid in water (A) and acetonitrile (B), delivered at 0.3 mL/min. The gradient was 95% A at 0–3 min; 90% A at 3–8 min; 90–75% A at 8–12 min; 75–70% A at 12–16 min; 70–45% A at 16–21 min; 45–5% A at 21–25 min; 5–95% A at 25–26 min; and 95% A at 26–30 min. The injection volume was 2 μL.
Mass spectrometry was performed on a Q Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) with a heated electrospray ionization source. Data were acquired separately in positive and negative ion modes over m/z 100–1500. The source parameters were sheath gas (N2), 30 arbitrary units; auxiliary gas (N2), 10 arbitrary units; capillary temperature, 320 °C; source heater temperature, 350 °C; and spray voltage magnitude, 3.0 kV. MS1 spectra were acquired in full-scan mode at a resolution of 35,000. MS2 spectra were obtained by data-dependent acquisition of the three most intense precursor ions with a normalized collision energy of 30%. Compounds were assigned from accurate mass, MS/MS fragmentation, and, where available, comparison of retention time and spectra with reference standards.
4.3. Candidate Compound Screening and Target Prediction
Because MEA was administered by oral gavage in the in vivo study, the 77 detected constituents were queried in the TCMSP platform (version 2.3) [27] and filtered using the conventional pharmacokinetic screening criteria of predicted oral bioavailability (OB) ≥ 30% (reflecting predicted gastrointestinal absorption and first-pass metabolic stability) and drug-likeness (DL) ≥ 0.18 (based on the average Tanimoto similarity of small-molecule drugs in DrugBank) to prioritize candidate orally absorbable small molecules for exploratory network construction. Six compounds met these thresholds, comprising two reference-standard-confirmed constituents (ellagic acid and quercetin) and four constituents tentatively assigned from accurate mass and MS/MS fragmentation (kaempferol, isorhamnetin, betulinic acid, and β-sitosterol). Because fixed OB and DL cutoffs may exclude bioactive glycosides, tannins, or triterpenoids that act via intestinal metabolites or local signaling, this filtering was used for candidate prioritization in network construction. Compound-related targets were predicted using SwissTargetPrediction (2019 version), Super-PRED (version 3.0), and PharmMapper (2017 version) [28,29,30]. Target names were standardized to official human gene symbols using UniProt (release 2023_05) [31], and duplicates were removed. ALI-related targets were collected from GeneCards (version 5.18), OMIM (2023 release), and the Therapeutic Target Database (TTD, 2024 update) using “acute lung injury” as the search term [32,33,34]. The intersection of compound-related and ALI-related targets was defined as the candidate MEA-ALI target set.
4.4. PPI Network Construction, Hub-Target Screening, and Enrichment Analysis
Candidate MEA-ALI targets were submitted to STRING (version 12.0) for protein–protein interaction (PPI) analysis, with the organism set to Homo sapiens and the minimum required interaction score set to greater than 0.7 [35]. The interaction file was imported into Cytoscape (version 3.9.1) for visualization and network analysis [36]. Gene Ontology (GO) enrichment analysis was performed for biological process, cellular component, and molecular function categories, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was used to identify disease-relevant signaling pathways. The 120 candidate targets were ranked with the cytoHubba plug-in (version 0.1) using maximal clique centrality, degree, closeness, and betweenness [37]. The top 10 targets from each algorithm were extracted, and their intersection was defined as the core target set. A compound–target–disease network was constructed to show the relationships among MEA, the candidate compounds, ALI, and the core targets, which were further subjected to GO/KEGG enrichment analyses.
4.5. Molecular Docking
Exploratory molecular docking was performed to evaluate theoretical binding complementarity between candidate MEA constituents and inflammation-related proteins. While binding energies were calculated across the six TCMSP-screened candidate compounds and the core targets, four representative complexes were selected for detailed structural visualization to cover two upstream network hubs (NFKB1 and EGFR) and two focal inflammasome-related proteins (caspase-1 and NLRP3), paired with the two reference-standard-confirmed candidate polyphenols (ellagic acid for caspase-1 and quercetin for NLRP3) and two candidate flavonoids (kaempferol for NFKB1 and isorhamnetin for EGFR). Crystal structures were obtained from the RCSB Protein Data Bank (NFKB1, PDB ID 1VKX; EGFR, 1M17; caspase-1, 1RWK; NLRP3, 7PZC). Using AutoDockTools (version 1.5.7; The Scripps Research Institute, La Jolla, CA, USA), crystallographic water molecules and non-interacting heteroatoms were removed, polar hydrogen atoms were added, and Kollman charges were assigned to the receptors; three-dimensional ligand structures from PubChem were energy-minimized and assigned Gasteiger partial charges with rotatable bonds defined. Docking grid boxes were centered on the active or ligand-binding pockets as follows: NFKB1 (1VKX), center (x = −19.5, y = 21.1, z = 99.5) Å, size 22 × 22 × 22 Å; EGFR (1M17), center (x = 22.0, y = 0.3, z = 52.8) Å, size 24 × 20 × 20 Å; caspase-1 (1RWK), center (x = 34.8, y = 61.0, z = 2.5) Å, size 24 × 24 × 24 Å; and NLRP3 (7PZC), center (x = 192.9, y = 204.7, z = 119.7) Å, size 24 × 24 × 24 Å. Docking was executed in AutoDock Vina (version 1.2.0; exhaustiveness = 16) [38] after verifying pocket coordinates against native co-crystallized ligand positions, and predicted binding energies were reported in kcal/mol. Two-dimensional interaction maps and three-dimensional docking-site views were generated using Discovery Studio Visualizer (version 2021; Dassault Systèmes, San Diego, CA, USA) and PyMOL (version 2.5; Schrödinger, LLC, New York, NY, USA) for representative complexes.
4.6. Cell Culture and Cytotoxicity Assay
MH-S cells were obtained from the China Center for Type Culture Collection (Wuhan, China) and maintained in RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37 °C in 5% CO2. Cytotoxicity was assessed using a Cell Counting Kit-8 (CCK-8) assay (Beyotime Biotechnology, Shanghai, China). Cells were seeded in 96-well plates at 7 × 103 cells per well and incubated overnight, followed by treatment with MEA (0, 20, 40, 80, 160, or 320 μg/mL; final DMSO < 0.1% v/v across all wells) for 24 h. CCK-8 reagent was added for 1.5 h in the dark, and absorbance was measured at 450 nm. Technical replicate wells were averaged within each experiment to yield one value per run, and three independent biological experiments (n = 3) were performed on different days using independent cell passages and freshly prepared working dilutions.
4.7. Cellular Inflammatory Model and Treatment
MH-S cells were assigned to Control, LPS, DEX, and MEA treatment groups. MEA was dissolved in sterile DMSO and diluted in complete RPMI 1640 medium to 20, 40, or 80 μg/mL, with a final DMSO concentration below 0.1% (v/v); Control and LPS groups received medium containing the equivalent concentration of DMSO vehicle (<0.1% v/v). DEX was used as a positive anti-inflammatory control at 1 μg/mL based on preliminary testing and established LPS-stimulated macrophage protocols [15]. Cells were seeded in 6-well plates at 5 × 105 cells per well and incubated overnight. MEA or DEX was added 2 h before stimulation with LPS (1 μg/mL) for 24 h. Supernatants were collected for ELISA and nitrite measurement, and cells were used for intracellular oxidative fluorescence imaging and RT-qPCR. Each cellular assay was performed in three independent biological experiments (n = 3) conducted on separate days using independent cell cultures and freshly prepared treatment solutions.
4.8. Intracellular ROS Measurement
After treatment, cells were incubated with 10 μM 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) at 37 °C for 30 min in the dark. Fluorescence images were acquired at excitation/emission wavelengths of 488/525 nm under identical acquisition settings for all groups. The mean green-channel intensity of each whole field was quantified in ImageJ (version 1.53t; National Institutes of Health, Bethesda, MD, USA) and expressed in arbitrary units. Each group contributed one value from each of three independent experiments. DCFH-DA fluorescence was used to assess intracellular ROS-related oxidation [21].
4.9. Nitrite Assay
Nitric oxide production was estimated from nitrite concentrations in MH-S cell supernatants using a Griess kit (Beyotime Biotechnology, Shanghai, China). Standards and samples were added to 96-well plates, followed by Griess reagents I and II. Absorbance was measured at 540 nm, and nitrite concentrations were calculated from the standard curve and expressed relative to the LPS group.
4.10. Animals and Experimental Design
Sixty male C57BL/6J mice (6–8 weeks old, 20 ± 2 g) were obtained from Hunan Slack Jingda Experimental Animal Co., Ltd. (Changsha, China) as an independent animal cohort distinct from our previously published multi-omics study [15]. Male mice were used to minimize estrous-cycle-associated hormonal variability in acute LPS-induced innate immune responses. Animals were housed at Hunan University of Medicine with standard chow and water available ad libitum under a 12 h light/dark cycle at 20–26 °C. The protocol was approved by the Medical Ethics Committee of Hunan University of Medicine (approval no. 2024(A01001); approved on 6 January 2024).
After five days of acclimation, mice were randomly assigned to six groups (n = 10 per group): Control, LPS, DEX (5 mg/kg), and MEA (100, 200, or 400 mg/kg). Control and LPS mice received an equivalent volume of 0.9% saline, whereas the other groups received prophylactic oral gavage of DEX or MEA once daily for 7 days. One hour after the final administration, systemic endotoxemia-associated ALI was induced by intraperitoneal injection of LPS (20 mg/kg), which reproducibly triggers acute pulmonary microvascular barrier dysfunction, edema, and leukocyte recruitment [7,15,26]; Control mice received an equal volume of sterile saline. Samples were collected 12 h after LPS challenge during the acute hyperinflammatory phase. The doses of DEX (5 mg/kg) and MEA (100, 200, and 400 mg/kg) and the 7-day pretreatment schedule were selected based on preliminary dose-ranging experiments and established murine ALI protocols [7,15].
4.11. Specimen Collection and Lung Wet/Dry Ratio
At 12 h after LPS challenge, mice were anesthetized by intraperitoneal injection of ketamine (80–100 mg/kg) and xylazine (10 mg/kg). Adequate anesthetic depth was confirmed by loss of the pedal withdrawal reflex. Blood was collected, and mice were then euthanized by cervical dislocation under deep anesthesia in accordance with the AVMA Guidelines for the Euthanasia of Animals (2020 Edition) [39]. Death was confirmed by the absence of spontaneous respiration, heartbeat, and reflexes. Serum was isolated by centrifugation at 3000 rpm for 30 min at 4 °C and stored at −80 °C. Lungs were excised immediately and allocated for histology, RNA extraction, protein analysis, and wet/dry measurement. For the wet/dry assay, fresh lung tissue was weighed, dried at 60 °C for 48 h to constant mass, and weighed again; the wet/dry ratio was calculated as wet mass divided by dry mass.
4.12. Hematoxylin and Eosin Staining
Paraformaldehyde-fixed lung tissues were dehydrated through graded ethanol, embedded in paraffin, and sectioned at 5 μm. Sections were stained with hematoxylin and eosin (H&E) using standard procedures and examined qualitatively under a ZEISS light microscope (Carl Zeiss, Oberkochen, Germany) to evaluate morphological alterations, including alveolar septal thickening and inflammatory cell infiltration.
4.13. ELISA
IL-1β, IL-6, and TNF-α concentrations in MH-S cell supernatants and mouse serum were measured using ELISA kits from MultiSciences Biotech (Hangzhou, China) according to the manufacturer’s instructions. Absorbance was recorded at 450 nm, and concentrations were calculated from the corresponding standard curves.
4.14. Western Blotting
Mouse lung tissue was homogenized in RIPA buffer containing a protease inhibitor cocktail, and protein concentrations were determined by BCA assay. Equal amounts of protein were separated by 8% or 12% SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% non-fat milk in TBST for 1.5 h at room temperature and incubated with primary antibodies overnight at 4 °C. After washing, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Bands were detected by enhanced chemiluminescence and quantified in ImageJ (version 1.53t; National Institutes of Health, Bethesda, MD, USA). Primary antibodies were anti-NLRP3 (Proteintech, Wuhan, China, Cat. No. 19771-1-AP; 1:1000), anti-ASC (Proteintech, Cat. No. 10500-1-AP; 1:5000), anti-caspase-1 (Proteintech, Cat. No. 22915-1-AP; 1:1000), anti-GSDMD/GSDMD-N (Wanleibio, Shenyang, China, Cat. No. WL04008; 1:1000), and anti-β-actin (Proteintech, Cat. No. 60008-1-Ig; 1:5000). In accordance with manufacturer validation for murine tissue, the ~45 kDa band detected by the caspase-1 antibody was quantified as pro-caspase-1, and the ~30 kDa cleavage band detected by the GSDMD antibody was quantified as GSDMD-N. To compare all six experimental groups side by side on the same blot without inter-membrane transfer variability, three mice per group were randomly selected in a blinded manner from the ten mice in each group, and one lung sample from each of the six groups was loaded per 6-lane gel across three independent membranes (n = 3 independent biological replicates per group). Target band intensities were normalized to β-actin, whose band intensity remained stable across groups.
4.15. Quantitative PCR
Total RNA was isolated from MH-S cells and mouse lung tissue using the RNA/Protein Extraction Kit (Beyotime Biotechnology, Shanghai, China). cDNA was synthesized with the All-in-one First Strand cDNA Synthesis Kit III (Seven Biotech, Beijing, China), and qPCR was performed using 2× SYBR Green qPCR MasterMix II (Seven Biotech). Relative expression was calculated using the 2−ΔΔCt method [40], with Actb (β-actin) as the endogenous reference gene; Actb cycle threshold (Ct) values showed no significant variation across experimental groups in either MH-S cells or lung tissue. Primer sequences are listed in Table 4.
Table 4.
Primer sequences used for RT-qPCR.
| Gene | Forward Primer (5′–3′) | Reverse Primer (5′–3′) |
|---|---|---|
| Nlrp3 | TCACAACTCGCCCAAGGAGAA | AAGAGACCACGGCAGAAGCTAG |
| Pycard (ASC) | CTGCTCAGATACAGCCAGAAC | CTGTCCTTCAGTCAGCACACTG |
| Gsdmd | GGTGCTTGACTCTGGGAACTG | GCTGCTTTGACAGCACCGTTGT |
| Casp1 | GGCACATTTCCAGGACTGACTG | GCAAGACGTGTACGAGTGGTTG |
| Actb (β-actin) | CATGCTGACAGATGCAGAAGG | TGCTGGAAGGTGGACAGTGAGG |
Abbreviations: ASC, apoptosis-associated speck-like protein containing a CARD; RT-qPCR, reverse transcription quantitative polymerase chain reaction.
4.16. Statistical Analysis
Data are presented as mean ± standard deviation (SD). Cellular assays comprised three independent biological experiments (n = 3) performed on separate days, with technical replicate wells averaged within each independent run prior to statistical analysis so that statistical tests were conducted strictly on independent biological units. Animal analyses included 10 independent mice per group (n = 10), except for Western blot densitometry, which included three randomly selected independent mice per group (n = 3). Prior to parametric testing, data normality and homogeneity of variance were assessed using the Shapiro–Wilk test and the Brown–Forsythe test, respectively, in GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA). Group differences were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons post hoc test. p < 0.05 was considered statistically significant.
4.17. Conceptual Illustration
Figure 12 provides a conceptual overview of the chemical profiling and cellular and animal findings. Data visualization and figure plotting were performed in Python (version 3.10; Python Software Foundation, Wilmington, DE, USA), and the final schematic and figures were prepared and reviewed by the authors.
5. Conclusions
Prophylactic administration of MEA suppressed LPS-induced inflammatory mediator production and DCFH-DA-detectable intracellular oxidative fluorescence in MH-S alveolar macrophages and attenuated histological lung injury, pulmonary edema, and circulating cytokines in an intraperitoneal LPS-induced mouse model of ALI. These protective effects were accompanied by decreased expression of Nlrp3, Pycard, Casp1, and Gsdmd mRNA as well as lower lung protein levels of NLRP3, ASC, pro-caspase-1, and ~30 kDa GSDMD-N. Together, these findings support the preventive anti-inflammatory activity of this Dong ethnomedicine preparation and provide a foundation for further constituent-level and functional mechanistic investigations.
Acknowledgments
During the preparation of this manuscript, the authors used ChatGPT (6 Astra, OpenAI, San Francisco, CA, USA) and Antigravity (Gemini 4 Argon, Google, Mountain View, CA, USA) for language polishing. The authors have reviewed and edited the content and take full responsibility for the content of this publication.
Abbreviations
ALI, acute lung injury; ANOVA, analysis of variance; ARDS, acute respiratory distress syndrome; ASC, apoptosis-associated speck-like protein containing a CARD; CCK-8, Cell Counting Kit-8; DCFH-DA, 2′,7′-dichlorodihydrofluorescein diacetate; DEX, dexamethasone; DL, drug-likeness; ELISA, enzyme-linked immunosorbent assay; GO, Gene Ontology; GSDMD, gasdermin D; GSDMD-N, N-terminal fragment of gasdermin D; H&E, hematoxylin and eosin; KEGG, Kyoto Encyclopedia of Genes and Genomes; LPS, lipopolysaccharide; MDA, Madeng’ai; MEA, ethyl acetate fraction of the ethanolic extract of Madeng’ai; NLRP3, NOD-like receptor family pyrin domain-containing 3; OB, oral bioavailability; PPI, protein–protein interaction; ROS, reactive oxygen species; RT-qPCR, reverse transcription quantitative polymerase chain reaction; UHPLC-MS, ultra-high-performance liquid chromatography–mass spectrometry.
Supplementary Materials
The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/ijms27219430/s1.
Author Contributions
Z.Z.: conceptualization, supervision, and funding acquisition. Y.Z.: investigation, formal analysis, visualization, and writing—original draft. W.J.: investigation and formal analysis. Y.W.: investigation and formal analysis. L.C.: resources. W.W.: supervision, funding acquisition, and writing—review and editing. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
All animal procedures were approved by the Medical Ethics Committee of Hunan University of Medicine (approval no. 2024(A01001), and approved on 6 January 2024).
Informed Consent Statement
Not applicable.
Data Availability Statement
The data supporting the findings of this study are available from the corresponding authors upon reasonable request. Uncropped Western blot images are provided separately as source data for editorial review.
Conflicts of Interest
The authors report no conflicts of interest in this work.
Funding Statement
This work was supported by the Hunan Provincial Key Laboratory of Dong Medicine, Hunan University of Medicine (Grant No. 2021-01); the Natural Science Foundation of Hunan Province (Grant No. 2023JJ30441); the Scientific Research Project of the Education Department of Hunan Province (Grant No. 25B0969); and the Research Foundation of the Administration of Traditional Chinese Medicine of Hunan Province (Grant No. B2023145).
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.Matthay M.A., Zemans R.L., Zimmerman G.A., Arabi Y.M., Beitler J.R., Mercat A., Herridge M., Randolph A.G., Calfee C.S. Acute respiratory distress syndrome. Nat. Rev. Dis. Primers. 2019;5:18. doi: 10.1038/s41572-019-0069-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Thompson B.T., Chambers R.C., Liu K.D. Acute respiratory distress syndrome. N. Engl. J. Med. 2017;377:562–572. doi: 10.1056/NEJMra1608077. [DOI] [PubMed] [Google Scholar]
- 3.Broz P., Dixit V.M. Inflammasomes: Mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 2016;16:407–420. doi: 10.1038/nri.2016.58. [DOI] [PubMed] [Google Scholar]
- 4.Swanson K.V., Deng M., Ting J.P.Y. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019;19:477–489. doi: 10.1038/s41577-019-0165-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Shi J., Zhao Y., Wang K., Shi X., Wang Y., Huang H., Zhuang Y., Cai T., Wang F., Shao F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660–665. doi: 10.1038/nature15514. [DOI] [PubMed] [Google Scholar]
- 6.Liu X., Zhang Z., Ruan J., Pan Y., Magupalli V.G., Wu H., Lieberman J. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153–158. doi: 10.1038/nature18629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Grailer J.J., Canning B.A., Kalbitz M., Haggadone M.D., Dhond R.M., Andjelkovic A.V., Zetoune F.S., Ward P.A. Critical role for the NLRP3 inflammasome during acute lung injury. J. Immunol. 2014;192:5974–5983. doi: 10.4049/jimmunol.1400368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Jones H.D., Crother T.R., Gonzalez-Villalobos R.A., Jupelli M., Chen S., Dagvadorj J., Arditi M., Shimada K. The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury. Am. J. Respir. Cell Mol. Biol. 2014;50:270–280. doi: 10.1165/rcmb.2013-0087OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Tomczyk M., Latté K.P. Potentilla—A review of its phytochemical and pharmacological profile. J. Ethnopharmacol. 2009;122:184–204. doi: 10.1016/j.jep.2008.12.022. [DOI] [PubMed] [Google Scholar]
- 10.Tang Z., Zhao Y., Zhang Z., Yue H., Wang D., Liu S., Tang H. Study of the antimicrobial activity of the Chinese Dong ethnic minority medicine, Madeng’ai. Evid. Based Complement. Altern. Med. 2022;2022:3678240. doi: 10.1155/2022/3678240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Cai W., Li K., Qin S., Xiong P., Peng J., Shi S., Zhang Z. Rapid identification and systematic mechanism of flavonoids from Potentilla freyniana Bornm. based on UHPLC-Q-Exactive Orbitrap mass spectrometry and network pharmacology. Int. J. Anal. Chem. 2021;2021:6619959. doi: 10.1155/2021/6619959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wu J., Zhang Z.Q., Zhou X.D., Yao Q.Y., Chen Z.L., Chu L.L., Yu H.H., Yang Y.P., Li B., Wang W. New terpenoids from Potentilla freyniana Bornm. and their cytotoxic activities. Molecules. 2022;27:3665. doi: 10.3390/molecules27123665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ji W., Zhang Y., Ji W., Zhang H., Qin B., Xing X.L., Zhang Z. Pomolic acid induces ferroptosis-mediated cell death in non-small cell lung cancer. Front. Pharmacol. 2025;16:1567942. doi: 10.3389/fphar.2025.1567942. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Liu K., Liu C., Wu C., Lei S., Bao Z., Yu C., Zou M., Zhang X., Zhang H., Zhang H., et al. Potentilla freyniana Bornm. and its active component tangeretin ameliorate gouty arthritis by inhibiting the MAPK/NF-κB/NLRP3 signaling pathway. J. Ethnopharmacol. 2026;358:121013. doi: 10.1016/j.jep.2025.121013. [DOI] [PubMed] [Google Scholar]
- 15.Zhang Z., Zhu T., Cao L., Wang Y., Xing X.L., Zhang Z. Protective effects of the ethyl acetate fraction from Madeng’ai on lipopolysaccharide-induced acute lung injury in mice: Insights from integrated multi-omics analysis. J. Ethnopharmacol. 2026;366:121650. doi: 10.1016/j.jep.2026.121650. [DOI] [PubMed] [Google Scholar]
- 16.Chen S., Jiang H., Wu X., Fang J. Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes. Mediat. Inflamm. 2016;2016:9340637. doi: 10.1155/2016/9340637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.García-Niño W.R., Zazueta C. Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. Pharmacol. Res. 2015;97:84–103. doi: 10.1016/j.phrs.2015.04.008. [DOI] [PubMed] [Google Scholar]
- 18.Kim J.M., Heo H.J. The roles of catechins in regulation of systemic inflammation. Food Sci. Biotechnol. 2022;31:957–970. doi: 10.1007/s10068-022-01069-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Checker R., Sandur S.K., Sharma D., Patwardhan R.S., Jayakumar S., Kohli V., Sethi G., Aggarwal B.B., Sainis K.B. Potent anti-inflammatory activity of ursolic acid, a triterpenoid antioxidant, is mediated through suppression of NF-κB, AP-1 and NF-AT. PLoS ONE. 2012;7:e31318. doi: 10.1371/journal.pone.0031318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Schinella G., Aquila S., Dade M., Giner R., Recio M.C., Spegazzini E., de Buschiazzo P., Tournier H., Ríos J.L. Anti-inflammatory and apoptotic activities of pomolic acid isolated from Cecropia pachystachya. Planta Med. 2008;74:215–220. doi: 10.1055/s-2008-1034301. [DOI] [PubMed] [Google Scholar]
- 21.Kalyanaraman B., Darley-Usmar V., Davies K.J.A., Dennery P.A., Forman H.J., Grisham M.B., Mann G.E., Moore K., Roberts L.J., Ischiropoulos H. Measuring reactive oxygen and nitrogen species with fluorescent probes: Challenges and limitations. Free Radic. Biol. Med. 2012;52:1–6. doi: 10.1016/j.freeradbiomed.2011.09.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Dominic A., Le N.T., Takahashi M. Loop between NLRP3 inflammasome and reactive oxygen species. Antioxid. Redox Signal. 2022;36:784–796. doi: 10.1089/ars.2020.8257. [DOI] [PubMed] [Google Scholar]
- 23.Tschopp J., Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol. 2010;10:210–215. doi: 10.1038/nri2725. [DOI] [PubMed] [Google Scholar]
- 24.Coll R.C., Robertson A.A.B., Chae J.J., Higgins S.C., Muñoz-Planillo R., Inserra M.C., Vetter I., Dungan L.S., Monks B.G., Stutz A., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015;21:248–255. doi: 10.1038/nm.3806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Tomás-Barberán F.A., González-Sarrías A., García-Villalba R., Núñez-Sánchez M.A., Selma M.V., García-Conesa M.T., Espín J.C. Urolithins, the rescue of “old” metabolites to understand a “new” concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Mol. Nutr. Food Res. 2017;61:1500901. doi: 10.1002/mnfr.201500901. [DOI] [PubMed] [Google Scholar]
- 26.Matute-Bello G., Downey G., Moore B.B., Groshong S.D., Matthay M.A., Slutsky A.S., Kuebler W.M., Acute Lung Injury in Animals Study Group An official American Thoracic Society workshop report: Features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol. 2011;44:725–738. doi: 10.1165/rcmb.2009-0210ST. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ru J., Li P., Wang J., Zhou W., Li B., Huang C., Li P., Guo Z., Tao W., Yang Y., et al. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014;6:13. doi: 10.1186/1758-2946-6-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Daina A., Michielin O., Zoete V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47:W357–W364. doi: 10.1093/nar/gkz382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Nickel J., Gohlke B.O., Erehman J., Banerjee P., Rong W.W., Goede A., Dunkel M., Preissner R. SuperPred: Update on drug classification and target prediction. Nucleic Acids Res. 2014;42:W26–W31. doi: 10.1093/nar/gku477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Wang X., Shen Y., Wang S., Li S., Zhang W., Liu X., Lai L., Pei J., Li H. PharmMapper 2017 update: A web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45:W356–W360. doi: 10.1093/nar/gkx374. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.UniProt Consortium UniProt: The Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023;51:D523–D531. doi: 10.1093/nar/gkac1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Stelzer G., Rosen N., Plaschkes I., Zimmerman S., Twik M., Fishilevich S., Stein T.I., Nudel R., Lieder I., Mazor Y., et al. The GeneCards Suite: From gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinform. 2016;54:1–30. doi: 10.1002/cpbi.5. [DOI] [PubMed] [Google Scholar]
- 33.Amberger J.S., Bocchini C.A., Scott A.F., Hamosh A. OMIM.org: Leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res. 2019;47:D1038–D1043. doi: 10.1093/nar/gky1151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Zhou Y., Zhang Y., Zhao D., Yu X., Shen X., Zhou Y., Wang S., Qiu Y., Chen Y., Zhu F. TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024;52:D1465–D1477. doi: 10.1093/nar/gkad751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Szklarczyk D., Kirsch R., Koutrouli M., Nastou K., Mehryary F., Hachilif R., Gable A.L., Fang T., Doncheva N.T., Pyysalo S., et al. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638–D646. doi: 10.1093/nar/gkac1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–2504. doi: 10.1101/gr.1239303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Chin C.H., Chen S.H., Wu H.H., Ho C.W., Ko M.T., Lin C.Y. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 2014;8:S11. doi: 10.1186/1752-0509-8-S4-S11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455–461. doi: 10.1002/jcc.21334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Leary S., Underwood W., Anthony R., Cartner S., Grandin T., Greenacre C., Gwaltney-Brant S., McCrackin M.A., Meyer R., Miller D., et al. AVMA Guidelines for the Euthanasia of Animals: 2020 Edition. American Veterinary Medical Association; Schaumburg, IL, USA: 2020. [Google Scholar]
- 40.Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCT) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data supporting the findings of this study are available from the corresponding authors upon reasonable request. Uncropped Western blot images are provided separately as source data for editorial review.
